Cidara Therapeutics Inc logo

CDTX - Cidara Therapeutics Inc Share Price

$2.34 0.1  4.9%

Last Trade - 04/03/21

Small Cap
Market Cap £76.8m
Enterprise Value £56.1m
Revenue £8.65m
Position in Universe 4988th / 6640
Unlock CDTX Revenue
Relative Strength (%)
1m -14.9%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -49.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 20.9 12.1 9.30 19.7
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, CidaraTherapeutics Inc revenues decreased 42% to $12.1M. Net lossapplicable to common stockholders increased 82% to $74.9M.Revenues reflect a decrease in demand for the Company'sproducts and services due to unfavorable market conditions.Higher net loss reflects Research and development -increase of 50% to $65.9M (expense), Interest income(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for CDTX
Graphical History


CDTX Revenue Unlock CDTX Revenue

Net Income

CDTX Net Income Unlock CDTX Revenue

Normalised EPS

CDTX Normalised EPS Unlock CDTX Revenue

PE Ratio Range

CDTX PE Ratio Range Unlock CDTX Revenue

Dividend Yield Range

CDTX Dividend Yield Range Unlock CDTX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CDTX EPS Forecasts Unlock CDTX Revenue
Profile Summary

Cidara Therapeutics Inc., is a clinical-stage biotechnology company focused on developing new anti-infectives. The Company’s lead product candidate is rezafungin acetate, which is a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. The Company is also leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated December 6, 2012
Public Since April 15, 2015
No. of Shareholders: 13
No. of Employees: 79
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 48,043,143
Free Float (0.0%)
Eligible for
CDTX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CDTX
Upcoming Events for CDTX
Frequently Asked Questions for Cidara Therapeutics Inc
What is the Cidara Therapeutics Inc share price?

As of 04/03/21, shares in Cidara Therapeutics Inc are trading at $2.34, giving the company a market capitalisation of £76.8m. This share price information is delayed by 15 minutes.

How has the Cidara Therapeutics Inc share price performed this year?

Shares in Cidara Therapeutics Inc are currently trading at $2.34 and the price has moved by -22.03% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cidara Therapeutics Inc price has moved by -36.94% over the past year.

What are the analyst and broker recommendations for Cidara Therapeutics Inc?

Of the analysts with advisory recommendations for Cidara Therapeutics Inc, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Cidara Therapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Cidara Therapeutics Inc next release its financial results?

Cidara Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Cidara Therapeutics Inc dividend yield?

Cidara Therapeutics Inc does not currently pay a dividend.

Does Cidara Therapeutics Inc pay a dividend?

Cidara Therapeutics Inc does not currently pay a dividend.

When does Cidara Therapeutics Inc next pay dividends?

Cidara Therapeutics Inc does not currently pay a dividend.

How do I buy Cidara Therapeutics Inc shares?

To buy shares in Cidara Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cidara Therapeutics Inc?

Shares in Cidara Therapeutics Inc are currently trading at $2.34, giving the company a market capitalisation of £76.8m.

Where are Cidara Therapeutics Inc shares listed? Where are Cidara Therapeutics Inc shares listed?

Here are the trading details for Cidara Therapeutics Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: CDTX
What kind of share is Cidara Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Cidara Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Cidara Therapeutics Inc share price forecast 2021?

Shares in Cidara Therapeutics Inc are currently priced at $2.34. At that level they are trading at 0.187% discount to the analyst consensus target price of 0.00.

Analysts covering Cidara Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.607 for the next financial year.

How can I tell whether the Cidara Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cidara Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -37.67%. At the current price of $2.34, shares in Cidara Therapeutics Inc are trading at -25.79% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cidara Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Cidara Therapeutics Inc.

Who are the key directors of Cidara Therapeutics Inc?

Cidara Therapeutics Inc's management team is headed by:

Jeffrey Stein - PRE
Paul Daruwala - COO
Daniel Burgess - CHM
Timothy Franson - IND
Taylor Sandison - OTH
Chrysa Mineo - IND
David Gollaher - IND
James Levine - CFO
Jessica Oien - GCN
Neil Abdollahian - OTH
Bonnie Bassler - DRC
Canale-Theakston .. - DRC
Christopher Kurtz - EVP
Who are the major shareholders of Cidara Therapeutics Inc?

Here are the top five shareholders of Cidara Therapeutics Inc based on the size of their shareholding:

Mundipharma AG Corporation
Percentage owned: 9.95% (4.78m shares)
BVF Partners L.P. Hedge Fund
Percentage owned: 7.78% (3.74m shares)
BB Biotech Fd Mutual Fund
Percentage owned: 5.87% (2.82m shares)
Bellevue Asset Management AG Investment Advisor
Percentage owned: 5.87% (2.82m shares)
5AM Ventures Venture Capital
Percentage owned: 4.18% (2.01m shares)
Similar to CDTX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.